切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2024, Vol. 13 ›› Issue (04) : 492 -497. doi: 10.3877/cma.j.issn.2095-3232.2024.04.009

所属专题: 述评 综述

专家论坛

自身免疫性胰腺炎诊治现状
王天福1, 王刚1,()   
  1. 1. 150001 哈尔滨医科大学附属第一医院胰胆外科 肝脾外科教育部重点实验室
  • 收稿日期:2024-03-27 出版日期:2024-08-10
  • 通信作者: 王刚
  • 基金资助:
    国家自然科学基金面上项目(82070657,82370651)

Diagnosis and treatment of autoimmune pancreatitis

Tianfu Wang1, Gang Wang1,()   

  1. 1. Department of Pancreaticobiliary Surgery, Key Laboratory of Liver and Spleen Surgery of the Ministry of Education, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
  • Received:2024-03-27 Published:2024-08-10
  • Corresponding author: Gang Wang
引用本文:

王天福, 王刚. 自身免疫性胰腺炎诊治现状[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 492-497.

Tianfu Wang, Gang Wang. Diagnosis and treatment of autoimmune pancreatitis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 492-497.

自身免疫性胰腺炎(autoimmune pancreatitis,AIP)是一种特殊类型的胰腺炎。由于其临床发病率较低,且不同地区流行病学特点不同,故对AIP诊治的认识仍未达成统一。AIP缺乏特异临床症状,早期诊断困难、误诊率高。本文围绕近年来多个AIP诊治指南,同时结合笔者自身的临床经验,对AIP的诊治现状进行探讨、分析,以期为提高其整体治愈率提供参考。

Autoimmune pancreatitis (AIP) is a special type of pancreatitis. Due to low clinical incidence and different epidemiological characteristics among regions, no consensus has been reached regarding the understanding of diagnosis and treatment of AIP. Due to lack of specific clinical symptoms, it is difficult to make an early diagnosis and the misdiagnosis rate is relatively high. In this article, based on recent guidelines on the diagnosis and treatment of AIP combined with clinical experience, research progress in the diagnosis and treatment of AIP was reviewed and analyzed, aiming to provide reference for improving the overall cure rate of AIP.

[1]
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7):1561-1568.
[2]
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology[J]. Pancreas, 2011, 40(3):352-358.
[3]
王刚, 丁乙轩, 孙备, 等. 自身免疫性胰腺炎21例临床分析[J]. 中华外科杂志, 2015, 53(9):680-684.
[4]
丁乙轩, 白雪巍, 王刚, 等. 自身免疫性胰腺炎的研究进展[J]. 中华肝胆外科杂志, 2014, 20(11):837-840.
[5]
吴丹, 邱秋, 唐亮, 等. 2009年至2018年我国自身免疫性胰腺炎患者临床特征分析[J]. 中华胰腺病杂志, 2020, 20(5):368-372.
[6]
Fukuda S, Akiyama S, Tarakji A, et al. Prevalence and clinical features of patients with autoimmune pancreatitis and inflammatory bowel disease: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(8):1474-1484.
[7]
Nista EC, de Lucia SS, Manilla V, et al. Autoimmune pancreatitis: from pathogenesis to treatment[J]. Int J Mol Sci, 2022, 23(20):12667.
[8]
Song TJ, Kim MH, Moon SH, et al. The combined measurement of total serum IgG and IgG4 may increase diagnostic sensitivity for autoimmune pancreatitis without sacrificing specificity, compared with IgG4 alone[J]. Am J Gastroenterol, 2010, 105(7):1655-1660.
[9]
Chang MC, Liang PC, Jan S, et al. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels[J]. Pancreatology, 2014, 14(5):366-372.
[10]
Jia H, Li J, Huang W, et al. Multimodel magnetic resonance imaging of mass-forming autoimmune pancreatitis: differential diagnosis with pancreatic ductal adenocarcinoma[J]. BMC Med Imaging, 2021, 21(1):149.
[11]
Ogawa H, Takehara Y, Naganawa S. Imaging diagnosis of autoimmune pancreatitis: computed tomography and magnetic resonance imaging[J]. J Med Ultrason, 2021, 48(4):565-571.
[12]
Ha J, Choi SH, Kim KW, et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(7):849-856.
[13]
Choi SY, Kim SH, Kang TW, et al. Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on the basis of contrast-enhanced MRI and DWI findings[J]. AJR Am J Roentgenol, 2016, 206(2):291-300.
[14]
Tang CYL, Chua WM, Cheng LTJ, et al. 18F-FDG PET/CT manifestations of IgG4-related disease[J]. Br J Radiol, 2021, 94(1124):20210105.
[15]
Ohtani M, Ofuji K, Akazawa Y, et al. Clinical usefulness of[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography for distinguishing between autoimmune pancreatitis and pancreatic cancer[J]. Pancreas, 2021, 50(7):1014-1019.
[16]
Sandrasegaran K, Menias CO. Imaging in autoimmune pancreatitis and immunoglobulin G4-related disease of the abdomen[J]. Gastroenterol Clin North Am, 2018, 47(3):603-619.
[17]
Guo T, Xu T, Zhang S, et al. The role of EUS in diagnosing focal autoimmune pancreatitis and differentiating it from pancreatic cancer[J]. Endosc Ultrasound, 2021, 10(4):280-287.
[18]
Cho MK, Moon SH, Song TJ, et al. Contrast-enhanced endoscopic ultrasound for differentially diagnosing autoimmune pancreatitis and pancreatic cancer[J]. Gut Liver, 2018, 12(5):591-596.
[19]
Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020[J].J Gastroenterol, 2022, 57(4):225-245.
[20]
Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study[J]. Gastrointest Endosc, 2016, 84(5):797-804, e1.
[21]
Morishima T, Kawashima H, Ohno E, et al. Prospective multicenter study on the usefulness of EUS-guided FNA biopsy for the diagnosis of autoimmune pancreatitis[J]. Gastrointest Endosc, 2016, 84(2):241-248.
[22]
Facciorusso A, Barresi L, Cannizzaro R, et al. Diagnostic yield of endoscopic ultrasound-guided tissue acquisition in autoimmune pancreatitis: a systematic review and meta-analysis[J]. Endosc Int Open, 2021, 9(1):E66-75.
[23]
Ishikawa T, Kawashima H, Ohno E, et al. Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study[J]. Endoscopy, 2020, 52(11):978-985.
[24]
Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1):1-6.
[25]
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7):1688-1699.
[26]
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience[J]. Gut, 2013, 62(11):1607-1615.
[27]
Tacelli M, Celsa C, Magro B, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(6):1061-1072, e8.
[28]
Sano T, Kikuta K, Takikawa T, et al. The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis[J]. Pancreatology, 2023, 23(1):112-119.
[29]
de Pretis N, Amodio A, Frulloni L. Updates in the field of autoimmune pancreatitis: a clinical guide[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7):705-709.
[30]
Hart PA, Levy MJ, Smyrk TC, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience[J]. Gut, 2016, 65(10):1702-1709.
[31]
Javed AA, Wright MJ, Ding D, et al. Autoimmune pancreatitis: a critical analysis of the surgical experience in an era of modern diagnostics[J]. Pancreas, 2021, 50(4):556-563.
[32]
Meng Q, Xin L, Liu W, et al. Diagnosis and treatment of autoimmune pancreatitis in China: a systematic review[J]. PLoS One, 2015, 10(6):e0130466.
[33]
Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58(11):1504-1507.
[34]
Khandelwal A, Inoue D, Takahashi N. Autoimmune pancreatitis: an update[J]. Abdom Radiol, 2020, 45(5):1359-1370.
[35]
徐嘉泽, 胡智明, 杨鸿国, 等. 自身免疫性胰腺炎的诊治进展[J]. 中华普通外科杂志, 2023, 38(1):70-73.
[36]
Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China[J]. Sci Rep, 2020, 10(1):4910.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[5] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[6] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[7] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[8] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[9] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[10] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[11] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 张平骥, 徐钰, 李天水, 庞文翼, 符师宁, 张梦圆. 重症患者镇静治疗现状及期望的调查研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 562-567.
[14] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?